Trials / Completed
CompletedNCT03264547
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 446 (actual)
- Sponsor
- Japan Breast Cancer Research Group · Academic / Other
- Sex
- Female
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pertuzumab | Every 3 weeks |
| DRUG | Trastuzumab | Every 3 weeks |
| DRUG | Docetaxel | Every 3 weeks |
| DRUG | Paclitaxel | Every week |
| DRUG | Eribulin | Administered for 2 weeks and is then stopped to be administered for 1 week |
Timeline
- Start date
- 2017-08-28
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2017-08-29
- Last updated
- 2025-09-29
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03264547. Inclusion in this directory is not an endorsement.